a Departments of Biochemistry and Molecular Biology , Virginia Commonwealth University , Richmond , VA , USA.
b Melanoma and Skin Cancer Program, Hillman Cancer Research Pavilion Laboratory , University of Pittsburgh Cancer Institute , Pittsburgh , PA , USA.
Cancer Biol Ther. 2019;20(5):700-710. doi: 10.1080/15384047.2018.1551747. Epub 2018 Dec 20.
There is no efficacious standard of care therapy for uveal melanoma. Unlike cutaneous disease, uveal melanoma does not exhibit RAS mutations but instead contains mutations with ~90% penetrance in either Gα or Gα. Previously we demonstrated that neratinib caused ERBB1/2/4 and RAS internalization into autolysosomes which resulted in their proteolytic degradation. In PDX isolates of uveal melanoma, neratinib caused the internalization and degradation of Gα and Gα in parallel with ERBB1 breakdown. These effects were enhanced by the HDAC inhibitor entinostat. Similar data were obtained using GFP/RFP tagged forms of K-RAS V12. Down regulation of Gα and Gα expression and RAS-GFP/RFP fluorescence required Beclin1 and ATG5. The [neratinib + entinostat] combination engaged multiple pathways to mediate killing. One was from ROS-dependent activation of ATM via AMPK-ULK1-ATG13-Beclin1/ATG5. Another pathway was from CD95 via caspase 8-RIP1/RIP3. A third was from reduced expression of HSP70, HSP90, HDAC6 and phosphorylation of eIF2α. Downstream of the mitochondrion both caspase 9 and AIF played roles in tumor cell execution. Knock down of ATM/AMPK/ULK-1 prevented ATG13 phosphorylation and degradation of RAS and Gα proteins. Over-expression of activated mTOR prevented ATG13 phosphorylation and suppressed killing. Knock down of eIF2α maintained BCL-XL and MCL-1 expression. Within 6h, [neratinib + entinostat] reduced the expression of the immunology biomarkers PD-L1, ODC, IDO-1 and enhanced MHCA levels. Our data demonstrate that [neratinib + entinostat] down-regulates oncogenic RAS and the two key oncogenic drivers present in most uveal melanoma patients and causes a multifactorial form of killing via mitochondrial dysfunction and toxic autophagy. Abbreviations: ERK: extracellular regulated kinase; PI3K: phosphatidyl inositol 3 kinase; ca: constitutively active; dn: dominant negative; ER: endoplasmic reticulum; AIF: apoptosis inducing factor; AMPK: AMP-dependent protein kinase; mTOR: mammalian target of rapamycin; JAK: Janus Kinase; STAT: Signal Transducers and Activators of Transcription; MAPK: mitogen activated protein kinase; PTEN: phosphatase and tensin homologue on chromosome ten; ROS: reactive oxygen species; CMV: empty vector plasmid or virus; si: small interfering; SCR: scrambled; IP: immunoprecipitation; VEH: vehicle; HDAC: histone deacetylase.
葡萄膜黑色素瘤尚无有效的标准治疗方法。与皮肤疾病不同,葡萄膜黑色素瘤不表现出 RAS 突变,而是含有约 90%外显率的 Gα 或 Gα 突变。此前我们证明,奈拉替尼导致 ERBB1/2/4 和 RAS 内吞进入自噬溶酶体,导致其蛋白水解降解。在葡萄膜黑色素瘤的 PDX 分离物中,奈拉替尼与 ERBB1 降解同时导致 Gα 和 Gα 的内化和降解。HDAC 抑制剂恩替诺特增强了这些作用。使用 GFP/RFP 标记的 K-RAS V12 形式获得了类似的数据。Gα 和 Gα 表达和 RAS-GFP/RFP 荧光的下调需要 Beclin1 和 ATG5。[奈拉替尼+恩替诺特]联合用药通过多种途径介导杀伤。一种是通过 ROS 依赖性激活 AMPK-ULK1-ATG13-Beclin1/ATG5 来激活 ATM。另一种途径是来自 CD95 通过 caspase 8-RIP1/RIP3。第三种途径是 HSP70、HSP90、HDAC6 的表达减少和 eIF2α 的磷酸化。线粒体下游,caspase 9 和 AIF 都在肿瘤细胞的执行中发挥作用。ATM/AMPK/ULK-1 的敲低阻止了 ATG13 的磷酸化和 RAS 和 Gα 蛋白的降解。激活的 mTOR 的过表达阻止了 ATG13 的磷酸化并抑制了杀伤。eIF2α 的敲低维持了 BCL-XL 和 MCL-1 的表达。在 6 小时内,[奈拉替尼+恩替诺特]降低了免疫生物学标志物 PD-L1、ODC、IDO-1 的表达,并增强了 MHCA 水平。我们的数据表明,[奈拉替尼+恩替诺特]下调了致癌 RAS 和大多数葡萄膜黑色素瘤患者中存在的两个关键致癌驱动因素,并通过线粒体功能障碍和毒性自噬引起多因素形式的杀伤。缩写:ERK:细胞外调节激酶;PI3K:磷脂酰肌醇 3 激酶;ca:组成性激活;dn:显性负;ER:内质网;AIF:凋亡诱导因子;AMPK:AMP 依赖性蛋白激酶;mTOR:哺乳动物雷帕霉素靶蛋白;JAK:Janus 激酶;STAT:信号转导和转录激活因子;MAPK:丝裂原激活蛋白激酶;PTEN:十号染色体上的磷酸酶和张力同源物;ROS:活性氧;CMV:空载体质粒或病毒;si:小干扰;SCR:随机;IP:免疫沉淀;VEH:载体;HDAC:组蛋白去乙酰化酶。